INVESTMENT SECURITIES, RELATED PARY

12 Months Ended

Sep. 30, 2022

Investment Securities Related Pary

INVESTMENT SECURITIES, RELATED PARY

NOTE 9. INVESTMENT SECURITIES, RELATED PARY

On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics, Inc.

On November 29, 2018 the Company accepted 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. in satisfaction of prepaid rent and accrued interest owed to the Company collectively amounting to $13,124.

On September 30,2022 the Company revalued 470,588 of the common shares of Zander Therapeutics, Inc. and 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs:

Fair Value of Intellectual Property	$	1,500
Prepaid Expenses		65,661
Due from Employee		1,071
Note Receivable		64,400
Accrued Interest Receivable		23,989
Investment Securities		8,423,366
Convertible Note Receivable		10,000
Accounts Payable		1,269,041
Notes Payable		400,000
Accrued Expenses Related Parties		162,011
Notes Payable Related Party		5396
Accrued Expenses		203,037
Enterprise Value		10,563,930
Less: Total Debt		(2,038,343	)
Portion of Enterprise Value Attributable to Shareholders		8,525,587
Fair Value Per Share	$	0.186168

The abovementioned constitute the Company’s sole related party investment securities as of September 30, 2022 

As of September 30, 2022:

470,588 Common Shares of Zander Therapeutics, Inc.                

Basis		Fair Value		Total Unrealized Gains		Net Unrealized Gain or (Loss) realized during the quarter ended September 30,2022
$	5,741	$	87,608	$	81,867	$	0

725,000 Series M Preferred of Zander Therapeutics, Inc.  

Basis		Fair Value		Total Unrealized Gain		Net Unrealized Gain or (Loss) realized during the quarter  ended September 30, 2022
$	13,124	$	134971	$	121,847	$	01